PRESS INQUIRIES

Mapp Biopharmaceutical, Inc.

We develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.

 
 

In the News

Mapp Bio Receives HHS Funding for Expanded Access Protocol for Ebola Treatment
Mapp Bio Receives HHS Funding for Expanded Access Protocol for Ebola Treatment

August 8, 2016

Mapp Bio
LeafBio Announces Conclusion of ZMapp™ Clinical Trial

February 23, 2016

dreamstime_s_45476267
Clinical Trials Begin on Antibody-based Prevention of HIV and Genital Herpes

January 7, 2016

PBS Newshour

PBS NewsHour – How to grow an Ebola vaccine with a tobacco plant
November 23, 2015

Publications

dreamstime_xs_43786685Monoclonal antibody therapy for Junin virus infection.
Apr 4, 2016

Antibody therapeutics for Ebola virus disease.
January 27, 2016

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.
Oct 2, 2014

A tripartite cocktail of chimeric monoclonal antibodies passively protects mice against ricin, staphylococcal enterotoxin B and Clostridium perfringens epsilon toxin.
Sept 27, 2014

READ MORE

© 2015 Mapp Biopharmaceauticals - Leaf Bio. All Rights Reserved.